Skip to content

Study · Case report or series · n = 1 · 2013

4 results

Acute tubulointerstitial nephritis following treatment with exenatide.

Nandakoban H, Furlong TJ, Flack JR

Diabetic medicine : a journal of the British Diabetic Association1 Jan 2013Cited by 24 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a man with type 2 diabetes, estimated glomerular filtration rate declined from 59 to 39 after exenatide treatment.

    In plain wordsIn one man, kidney filtration declined after exenatide treatment.

    Outcome
    DecreaseEstimated glomerular filtration rate during treatment
    Study

    n = 1

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    eGFR
    59 ml min(-1) 1.73 m(-2)
    before deterioration
    eGFR
    39 ml min(-1) 1.73 m(-2)
    after 2 months

    Source sentences

    Summary
    He subsequently developed deterioration in kidney function, with the estimated glomerular filtration rate declining from 59 to 39 ml min(-1) 1.73 m(-2) over 2 months.
    1 context sentence
    Summary · context
    A 58-year-old man was prescribed exenatide for poorly controlled Type 2 diabetes mellitus.
  2. 02HumanCase report or seriesSafety outcome

    In the same man, estimated glomerular filtration rate deteriorated to 16 despite exenatide cessation.

    In plain wordsIn one man, kidney filtration continued to decline after exenatide stopped.

    Outcome
    DecreaseEstimated glomerular filtration rate after cessation
    Study

    n = 1

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    eGFR
    16 ml min(-1) 1.73 m(-2)
    after exenatide cessation

    Source sentences

    Summary
    Despite cessation of exenatide, there was continued deterioration in estimated glomerular filtration rate to 16 ml min(-1) 1.73 m(-2).
    1 context sentence
    Summary · context
    A 58-year-old man was prescribed exenatide for poorly controlled Type 2 diabetes mellitus.
  3. 03HumanCase report or seriesSafety outcome

    In a man treated with exenatide, biopsy showed active diffuse tubulointerstitial nephritis with eosinophil infiltration.

    In plain wordsIn one man treated with exenatide, a kidney biopsy showed inflammation with eosinophils.

    Outcome
    Not applicableBiopsy-proven tubulointerstitial nephritis
    Study

    n = 1

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    He underwent renal biopsy and the sections showed active diffuse tubulointerstitial nephritis with infiltration of eosinophils.
    1 context sentence
    Summary · context
    A 58-year-old man was prescribed exenatide for poorly controlled Type 2 diabetes mellitus.
  4. 04HumanCase report or seriesSafety outcome

    In one man who developed biopsy-proven tubulointerstitial nephritis after starting exenatide, kidney function recovered incompletely after months of prednisolone.

    In plain wordsIn one man whose kidney inflammation followed exenatide treatment, kidney function recovered only partly after months of prednisolone.

    Outcome
    Direction not reportedIncomplete kidney recovery after exenatide-associated nephritis and prednisolone
    Study

    n = 1

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    He was treated with prednisolone over several months with incomplete recovery in kidney function.
    1 context sentence
    Summary · context
    A 58-year-old man was prescribed exenatide for poorly controlled Type 2 diabetes mellitus.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.